The present study aimed to investigate the influence of the angiotensin-converting enzyme (ACE)-inhibitor captopril and the Ca-antagonist nifedipine on endotheliumdependent vasodilation (EDV) in the forearm of hypertensive patients. Twenty-three middle-aged untreated hypertensive patients underwent evaluation of EDV and endothelium-independent vasodilation (EIDV) in the forearm, by means of local intra-arterial infusions of methacholine (MCh, evaluating EDV) and sodiumnitroprusside (SNP, evaluating EIDV), before and 1 h after intake of either captopril (25 mg) or nifedipine (10 mg) in a randomised, double-blind fashion. A matched normotensive control group was investigated at baseline conditions only. Five of the hypertensives were also evaluated after 3 months of treatment with captopril 25 mg twice daily in an open pilot study.
Introduction
By elaboration of several vasoactive factors such as nitric oxide (NO), endothelin-1 (ET-1), prostaglandins and yet unidentified endothelium-derived hyperpolarising factor (EDHF), the vascular endothelium plays a crucial role in the regulation of blood flow, peripheral resistance and thereby blood pressure (BP). 1 Several investigators have found an impaired endothelium-dependent vasodilation (EDV) in the forearm circulation in patients with primary hypertension, [2] [3] [4] [5] [6] [7] [8] [9] a defect that has been proposed to comprise a dysfunctional NO-system or an over-production of an endothelium derived contracting factor. Whether this endothelial dysfunction is a primary or secondary phenomenon of the hypertensive disease is so far not known. However, as a defect in endothelial function might be of pathogenetic importance in the development of primary hyper- Third, in the pilot study, 3 months of captopril treatment induced a significant potentiation of the vasodilator response to MCh (؉34 ؎ 17%, MCh 4 g/min, P Ͻ 0.05) in parallel with a significant BP reduction (؊22 ؎ 24/13 ؎ 13 mm Hg, P Ͻ 0.05), while the response to SNP was unchanged.
In conclusion, the present study confirmed that essential hypertension is associated with a defect in EDV. Furthermore, an improvement in EDV was seen in hypertensive patients shortly after administration of captopril, but not nifedipine. In addition, a significant beneficial effect on EDV was seen in a small pilot study during long-term treatment with captopril.
tension, 10 as well as promote vascular complications, 11 improving EDV in this patient group may be beneficial in several ways.
Previous investigations of the endothelial effects of anti-hypertensive medications have produced disappointing results, 8 even if there are some indications of a positive effect of angiotensin-converting enzyme (ACE)-inhibition. 4, 12 The present study aimed to investigate if the ACEinhibitor captopril or the Ca-antagonist nifedipine could improve EDV in the forearm vascular bed in untreated hypertensive patients. The acute effects induced by a single dose of captopril or nifedipine were investigated in a randomised, double-blind study, while the effects of long-term treatment with captopril was studied in a small, open pilot study.
Materials and methods

Subjects
The study population (Table 1) consisted of 23 patients (22 men and one woman) with essential hypertension defined as diastolic BP (DBP) Ͼ95 mm Hg without treatment confirmed by BP re- cordings at different locations. The presence of secondary hypertension was excluded by laboratory tests and physical examination. Another two subjects entered the trial, but were later excluded as secondary hypertension was discovered.
Ten of the patients were previously untreated and the remaining 13 had been without anti-hypertensive treatment for at least 3 weeks at the time of the investigation.
An age-and sex-matched normotensive (BP below 140/90 mm Hg) control population (n = 25, Table 1 ) was randomly recruited from the general population in the city of Uppsala. All controls were without history of cardiovascular disorders and were free from any medications.
Measurements of forearm blood flow (FBF)
During the blood flow measurements, the subjects were supine in a quiet room maintained at a constant temperature (21-23°C). An arterial cannula was inserted into the brachial artery of one arm for regional infusions of MCh (muscarinic agonist) and SNP (nitric oxide donor). Muscarinic agonists have previously been shown to induce EDV 13 while NO donors act as direct smooth muscle relaxants, inducing vasodilation independent of the endothelium.
The vasodilative drug-infusions were given during 5 min for each dose with a 20 min wash-out period between the two drugs. The infused dosages were 2 and 4 g/min for MCh and 5 and 10 g/min for SNP. These drugs were given in a random order at a rate of 1 ml/min.
Before and at the end of the different dosages of the two drugs, FBF was measured in both forearms by venous occlusion plethysmography according to the following. A mercury in-silastic strain gauge, connected to a calibrated plethysmograph, was placed on the upper third of the forearm, which rested comfortably slightly above the level of the heart. Venous occlusion was achieved by a BP cuff applied proximal to the elbow and inflated to 40 mm Hg by a rapid cuff inflator; approximately four inflations per minute, each of about 7 sec duration were performed. The vasodilative infusions were undertaken in one of the arms while the contralateral arm served as a control. Evaluations of FBF were made by calculations of the mean of five consecutive recordings. The reproducibility of this test of EDV and endothelium-independent vasodilation (EIDV) was evaluated in 10 healthy young volunteers in whom the investigation was performed before and after 2 h of intravenous saline infusion, as well as repeated after 2-3 weeks. Baseline resting FBF showed a variation less than 10%, while FBF during vasodilation induced by either MCh or SNP showed a variation of less than 5%, in the shortterm (2 h) as well as the long-term (2-3 weeks) perspective.
In the present study, the measurements of EDV and EIDV were undertaken at baseline conditions, 1 h after intake of either captopril or nifedipine (n = 21). Evaluations of the vasodilation in normotensive subjects were only undertaken at baseline conditions and no oral drugs were given in this group. BP measurements were made with a mercury sphygmomanometer in parallel with the FBF recordings.
The study protocol was approved by the Hospital ethics committee and informed consent was obtained from all participants.
Anti-hypertensive drugs
Captopril (25 mg, n = 12) or nifedipine (10 mg, n = 9) was administered orally in a randomised, doubleblind manner for the evaluation of the acute effects of these drugs.
Furthermore, five patients received 25 mg of captopril twice a day for 3-6 months in an open fashion in a pilot study. The follow-up measurements in these five patients were performed at least 8 h after intake of the last dose. The patients included in the long-term study were similar in demographies and BP distribution as the hypertensive sample as a whole.
Calculations
Mean artery pressure (MAP) was calculated as onethird of the pulse pressure (systolic BP (SBP) minus DBP) added to DBP.
Forearm vascular resistance (FVR) was given by MAP divided by FBF. In the present study vasodilation was evaluated by the reduction in FVR achieved by MCh or SNP-infusion in relation to baseline FVR, (FVR drug − FVR baseline )/FVR baseline .
Statistical analysis
Treatment effects were evaluated by two-way ANOVA in the short-term study and with the Wilcoxon signed rank sum test (two-tailed) in the longterm pilot study. Differences between groups were calculated by means of one-way ANOVA; P Ͻ 0.05 was regarded as significant.
Results
Baseline characteristics for the hypertensive subjects and the normotensive controls are given in Table 1 .
The hypertensive patients presented a significantly attenuated vasodilation induced by MChinfusion compared to the normotensive control subjects (P Ͻ 0.001 for both doses), while the response to SNP was not significantly different between patients and controls ( Figure 1 ).
Captopril, short-term effects
The baseline characteristics, as well as the vasodilation induced by MCh-or SNP-infusion, were comparable in the two groups before the drugs were given (Table 2) .
A significant reduction in MAP was observed in the hypertensive patients 1 h after administration of either captopril or nifedipine (from 157 ± 21/ 98 ± 12 to 146 ± 22/90 ± 13 mm Hg and from 158 ± 25/93 ± 12 to 147 ± 24/86 ± 14, respectively, ± s.d., P Ͻ 0.01 for changes within both of the groups, no significant difference between the drugs, Table 2 ). Although baseline FVR was unchanged 1 h after administration of captopril, the decrease in FVR induced by MCh (EDV) was significantly potentiated in this treatment group (P Ͻ 0.01 for both doses), while the FVR response to SNP (EIDV) was not significantly changed ( Figure 2a) . The improvement in MCh-induced vasodilation after captopril administration was significantly correlated to the decrease in MAP induced by the drug (r = 0.72, P Ͻ 0.01, Figure 3) .
Nifedipine, short-term effects
One hour after intake of nifedipine, neither baseline FVR, nor the FVR responses to MCh or SNP were significantly altered compared to baseline measurements (Figure 2b ). There was no significant relation between the relative change in MCh-induced vasodilation after nifedipine administration and the Figure 1 The forearm vasodilation in hypertensive patients compared to normotensive subjects. ***Denotes P Ͻ 0.0001 vs normotensive controls. The relative reduction in FVR in hypertensive patients, n = 23 ({) and in normotensive age-and sex-matched controls, n = 25 (Ǣ). FVR, forearm vascular resistance. MCh, methacholine, a muscarinic agonist inducing endotheliumdependent vasodilation. SNP, sodium-nitroprusside, a nitricoxide donor, inducing endothelium-independent vasodilation. Relative reduction in FVR 60 ± 17 64 ± 11 during SNP-infusion at 10 g/min (%) No significant differences between the two treatment groups concerning these baseline characteristics were found. MCh, methacholine; SNP, sodium-nitroprusside. Values are expressed as means ± standard deviation (s.d.). decrease in MAP induced by the drug (r = −0.10, Figure 4 ).
Captopril, long-term effects
Three to 6 months (19 ± 7 weeks) of treatment with captopril induced a significant reduction in BP (SBP from 166 ± 36 to 144 ± 18 mm Hg, DBP from 99 ± 8 to 86 ± 8 mm Hg, P Ͻ 0.05). Although baseline FVR was unchanged after long-term treatment, there was a significant potentiation of the FVR response to MCh compared to the measurements performed before treatment was initiated ( Figure 5 , P Ͻ 0.05). The decrease in FVR induced by SNP was not significantly altered by the long-term treatment.
No significant changes in FBF in the contralateral control arm were seen in any of the investigations, therefore no adjustment for changes in basal FBF was performed.
Discussion
The present study provides further evidence for a defect in EDV in patients with essential hypertension. Furthermore, a positive short-term effect of ACE-inhibition with captopril, but not nifedipine, on EDV in the forearm bed of hypertensive patients despite a similar reduction in BP by the two drugs was shown, in accordance with previous findings. 4 Also a withstanding potentiation of EDV by longterm treatment with captopril was found. Even if the latter result is based on a small, open pilot study and therefore the interpretation should be taken with great caution, the potentiation of EDV was uniform throughout the patient group, with some of the individuals demonstrating an impressive improvement (16-56%). 
Figure 3
The relation between the improvement in endotheliumdependent vasodilation and the reduction in BP 1 h after administration of captopril. The correlation between the relative improvement of forearm endothelium-dependent vasodilation and the reduction in mean artery pressure (MAP) 1 h after administration of captopril (25 mg). Endothelium-dependent vasodilation was induced by methacholine and evaluated as reduction in forearm vascular resistance, r = 0.72, P Ͻ 0.01.
Although Creager et al
8 found no positive effect on EDV in the forearm circulation by treatment with the ACE-inhibitors captopril and enalapril in a recent randomised trial in hypertensive patients, the longer duration of treatment in the present study (3-6 months vs 7-8 weeks) might contribute to the positive result. In fact, there was a strong, although not significant, tendency towards a positive relation between the treatment duration and the improvement in EDV in the present small long-term pilot study (r = 0.77, not significant). Thus, the encouraging findings in this pilot study suggests that larger, randomised trials with a sufficient duration of the treatment period are highly warranted to properly evaluate the effects of anti-hypertensive drugs, especially ACE-inhibitors, on endothelial function.
Concerning the short-term effect of captopril, it is Figure 4 The relation between the improvement in endotheliumdependent vasodilation and the reduction in BP 1 h after administration of nifedipine. The non-significant relation between the relative improvement of forearm endothelium-dependent vasodilation and the reduction in mean artery pressure (MAP) 1 h after administration of nifedipine (10 mg). Endothelium-dependent vasodilation was induced by methacholine and evaluated as reduction in forearm vascular resistance, r = 0.10.
evident that an acute improvement of endothelial function in the forearm of hypertensive patients is achieveable, as previously has been shown. 4 It is interesting to note that the defect EDV actually normalised in the hypertensive patients, since 1 h after captopril administration no significant difference in EDV between these hypertensive patients and normotensive subjects could be found. Furthermore, in the patients given captopril, the degree of acute BP reduction was related to the improvement in EDV, suggesting a close association between the BP level and endothelium vasodilator function.
However, an acute BP reduction does obviously not guarantee an improvement in the endothelial function, since nifedipine induced a similar reduction in BP without altering the response to either MCh or SNP. This might be interpreted in one of two ways. First, the degree of BP reduction by captopril is of no real importance, but rather an effect of captopril on endothelial function being independently related to the BP level. Second, nifedipine might directly or indirectly affect EDV in a way that counteracts any potential beneficial effects of the reduction in BP. As acute administration of nifedipine has been found to stimulate sympathetic outflow, as evaluated by increased levels of circulating catecholamines, 14 this effect may counteract any possible benefit for the endothelium induced by the BP reduction.
The present study did not investigate possible mechanisms mediating the endothelial effect of captopril. However, since vasodilation with muscarinic agonists have been shown to require an intact endothelium, 13 and only the response to MCh was affected by captopril treatment, the mechanisms mediating the vascular effect of this ACE-inhibitor are most likely endothelium-related. NO and ET-1 are two major endothelium-derived factors responsible for vasodilation and constriction, 1 both of these mediators have been suggested to mediate the effects of ACE-inhibition on EDV. 1 A positive local endothelial effect by the ACEinhibitor enalaprilat has previously been reported in the forearm in healthy volunteers. 15 Pretreatment with the NO-synthesis blocker L-NMMA abolished this beneficial effect, suggesting a mediation through the formation of NO. 15 Furthermore, pretreatment with acetylic salicylic acid did not affect the response to the ACE-inhibitor, making an involvement of prostanoids in this vascular action of enalaprilat less likely. 15 Another possibility is that ACE-inhibition affects the level of ET-1, as both enalaprilat and captopril have been shown to attenuate the ET-1 release from cultured umbilical endothelial cells in vitro. 16 The circulating levels of ET-1 have also been lowered by therapy with the ACE-inhibitor captopril in hypertensive patients, 17 suggesting that a part of the beneficial effect of ACE-inhibition on endothelial function might be mediated through ET-1. In addition, concomitant infusion of enalaprilat and ET-1 locally in the forearm blunted the vasoconstriction induced by ET-1 infusion only, 18 implying that ACE-inhibitors also might moderate the effects of ET-1 and not only the formation of this potent vasoconstrictor. Furthermore, ACE-inhibitors are known to increase the levels of bradykinin, as this vasodilator is degraded by the ACE. As bradykinin is a potent stimulator of NO formation, 19 the increased availibility of bradykinin during ACE inhibition would, by increased formation of NO, improve EDV. Furthermore, as angiotensin II has been proven to promote production of oxygen radicals by stimulation of NADH/NADPH-dependent oxidases, 20 ACEinhibition may also attenuate the formation of oxygen radicals and thereby prolong the half-life of NO.
In the present study there was a tendency that hypertension also affected EIDV and that treatment with captopril, both short-term and long-term, also improved EIDV. These tendencies were, however, not significant and it is therefore evident that although the effects of the hypertensive state and captopril administration might also affect EIDV to a minor degree, the main effects are on EDV.
In conclusion, the present study confirmed that essential hypertension is associated with a defect in EDV. Furthermore, a significant acute potentiation of EDV was seen in hypertensive patients after administration of captopril, but not nifedipine. In addition, the beneficial efect on EDV seen in a small pilot study of long-term treatment with captopril, would serve as an incitement to perform randomised, blinded studies to evaluate the long-term effects of anti-hypertensive treatment on endothelial function.
